Chen, Y., Gopalakrishnan, S. K., Ooi, M., Sultana, R., Lim, L. H., Grigoropoulos, N., . . . MEDICINE. (2021). A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). SPRINGERNATURE.
Chicago Style CitationChen, Yunxin, et al. A Phase 2 Study of Carfilzomib, Cyclophosphamide and Dexamethasone As Frontline Treatment for Transplant-eligible MM With High-risk Features (SGH-MM1). SPRINGERNATURE, 2021.
MLA引文Chen, Yunxin, et al. A Phase 2 Study of Carfilzomib, Cyclophosphamide and Dexamethasone As Frontline Treatment for Transplant-eligible MM With High-risk Features (SGH-MM1). SPRINGERNATURE, 2021.
警告：這些引文格式不一定是100％准確.